Skip to content

GREENWICH LIFESCIENCES, INC.: 10-Q filed 2025-08-14

What GREENWICH LIFESCIENCES, INC. reported in its quarterly report filed 2025-08-14 (fiscal Q2 2025): 23 published measures, 71 facts as tagged in accession 0001641172-25-024066.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-14
Fiscal period
fiscal Q2 2025
Accession
0001641172-25-024066 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GREENWICH LIFESCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-303,125,101USD
At 2024-12-314,093,769USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-301,685,609USD
At 2024-12-311,559,733USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-301,439,492USD
At 2025-03-311,312,311USD
At 2024-12-312,534,036USD
At 2024-06-305,875,432USD
At 2024-03-315,120,852USD
At 2023-12-316,700,409USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-303,125,101USD
At 2024-12-314,091,990USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,025,278USD91
2025-01-01 to 2025-06-30-7,283,640USD181
2025-01-01 to 2025-03-31-3,258,362USD90
2024-04-01 to 2024-06-30-2,606,682USD91
2024-01-01 to 2024-06-30-5,079,877USD182
2024-01-01 to 2024-03-31-2,473,195USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-4,067,557USD181
2024-01-01 to 2024-06-30-2,830,405USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-303,100,668USD181
2024-01-01 to 2024-06-303,065,856USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-73,437,018USD
At 2024-12-31-66,153,378USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3013,370,983shares91
2025-01-01 to 2025-06-3013,271,820shares181
2024-04-01 to 2024-06-3012,906,867shares91
2024-01-01 to 2024-06-3012,882,896shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3013,370,983shares91
2025-01-01 to 2025-06-3013,271,820shares181
2024-04-01 to 2024-06-3012,906,867shares91
2024-01-01 to 2024-06-3012,882,896shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.3USD/shares91
2025-01-01 to 2025-06-30-0.55USD/shares181
2024-04-01 to 2024-06-30-0.2USD/shares91
2024-01-01 to 2024-06-30-0.39USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.3USD/shares91
2025-01-01 to 2025-06-30-0.55USD/shares181
2024-04-01 to 2024-06-30-0.2USD/shares91
2024-01-01 to 2024-06-30-0.39USD/shares182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-303,088,428USD181
2024-01-01 to 2024-06-301,189,044USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,045,953USD91
2025-01-01 to 2025-06-30-7,328,285USD181
2024-04-01 to 2024-06-30-2,661,404USD91
2024-01-01 to 2024-06-30-5,198,605USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-301,685,609USD
At 2024-12-311,559,733USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-12-311,779USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-304,045,953USD91
2025-01-01 to 2025-06-307,328,285USD181
2024-04-01 to 2024-06-302,661,404USD91
2024-01-01 to 2024-06-305,198,605USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-303,507,906USD91
2025-01-01 to 2025-06-306,109,028USD181
2024-04-01 to 2024-06-302,307,873USD91
2024-01-01 to 2024-06-304,502,386USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3013,472,939shares
At 2024-12-3113,152,729shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-303,125,101USD
At 2024-12-314,091,990USD
At 2024-06-307,224,875USD
At 2023-12-316,989,424USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-7,283,640USD181
2024-01-01 to 2024-06-30-5,079,877USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30538,047USD91
2025-01-01 to 2025-06-301,219,257USD181
2024-04-01 to 2024-06-30353,531USD91
2024-01-01 to 2024-06-30696,219USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30118,940USD181
2024-01-01 to 2024-06-301,078,914USD182

Inspect the source

Entity
GREENWICH LIFESCIENCES, INC. / CIK 0001799788
Captured
2026-09-21T17:27:54.821Z
SEC response SHA-256
a617dbe92932ff09e9921f2bebe266085b6d33d46c3d873a6ff42dd23172a3bb

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001799788.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))